SummaryPregabalin, commonly referred to as Lyrica®, is a well-known anticonvulsant medication, which has found its footing in the treatment of various medical conditions. Such conditions include but are not limited to anxiety disorders, epilepsy, and neuralgia. The mechanism of action that characterizes pregabalin's utility involves blocking the CACNA2D1 and CACNA2D2 calcium channels, thus effectively targeting these disorders with aplomb. The Upjohn Co. received approval for the medical use of pregabalin in the European Union as far back as 2004, indicating that the medication has been a key feature of medical treatment for some time. Pregabalin's indications primarily target the treatment of neuropathic pain conditions, including fibromyalgia, and partial onset seizures in combination with other anticonvulsant medications. These conditions are managed with pregabalin due to its efficacy in minimizing their attendant symptoms. Pregabalin, therefore, serves as a vital tool in the management of chronic pain and neurological disorders. |
Drug Type Small molecule drug |
Synonyms LYRICA CR + [10] |
Target |
Action blockers |
Mechanism CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers), CACNA2D2 blockers(Voltage-gated calcium channel alpha2/delta subunit 2 blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (05 Jul 2004), |
RegulationSpecial Review Project (China), Priority Review (China) |
Molecular FormulaC8H17NO2 |
InChIKeyAYXYPKUFHZROOJ-ZETCQYMHSA-N |
CAS Registry148553-50-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02716 | Pregabalin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Fibromyalgia | United States | 21 Jun 2007 | |
Seizures | Australia | 13 Apr 2005 | |
Neuralgia, Postherpetic | United States | 30 Dec 2004 | |
Epilepsies, Partial | Norway | 05 Jul 2004 | |
Epilepsies, Partial | Iceland | 05 Jul 2004 | |
Epilepsies, Partial | European Union | 05 Jul 2004 | |
Epilepsies, Partial | Liechtenstein | 05 Jul 2004 | |
Epilepsy | Iceland | 05 Jul 2004 | |
Epilepsy | Liechtenstein | 05 Jul 2004 | |
Epilepsy | European Union | 05 Jul 2004 | |
Epilepsy | Norway | 05 Jul 2004 | |
Generalized anxiety disorder | Liechtenstein | 05 Jul 2004 | |
Generalized anxiety disorder | Iceland | 05 Jul 2004 | |
Generalized anxiety disorder | European Union | 05 Jul 2004 | |
Generalized anxiety disorder | Norway | 05 Jul 2004 | |
Neuralgia | Liechtenstein | 05 Jul 2004 | |
Neuralgia | Norway | 05 Jul 2004 | |
Neuralgia | Iceland | 05 Jul 2004 | |
Neuralgia | European Union | 05 Jul 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Generalized anxiety disorder | Discovery | Iceland | 25 Jun 2015 | |
Generalized anxiety disorder | Discovery | Liechtenstein | 25 Jun 2015 | |
Generalized anxiety disorder | Discovery | Norway | 25 Jun 2015 | |
Diabetic peripheral neuropathy | Discovery | United States | 30 Dec 2004 | |
Neuralgia, Postherpetic | Discovery | United States | 30 Dec 2004 |
Phase 4 | 84 | (Preoperative Adductor Canal Block Group) | ktxhphizyn(rjdhozomza) = hbhqqbvatc wbjnnkxbut (vdwfddmgid, ykrevxjpun - mfcrlbkbbk) View more | - | 12 Feb 2025 | ||
(Postoperative Adductor Canal Block Group) | ktxhphizyn(rjdhozomza) = owlfvlrknx wbjnnkxbut (vdwfddmgid, snzdglmkrm - hqigfvwdwo) View more | ||||||
Phase 2/3 | 118 | (Pregabalin 300mg) | ymyxqlcvyo(olbktzzsbv) = bbftbxkhnv lymqqjzlss (guzqcthkcz, ftpcfcigxg - nolzkvystl) View more | - | 24 Oct 2024 | ||
Placebo oral tablet (Placebo) | ymyxqlcvyo(olbktzzsbv) = snhvlzantw lymqqjzlss (guzqcthkcz, iwnnypvzmm - vvzfwjytmv) View more | ||||||
Phase 4 | - | 100 | (Multi-modal) | wqkjxvyucl(fzneclortk) = iqaoqlblzi oqmegxcbnt (udganeuxrf, oanftirqmf - nvahocoawn) View more | - | 08 Jul 2024 | |
(Control) | wqkjxvyucl(fzneclortk) = nozwyykclv oqmegxcbnt (udganeuxrf, bhnawuwjxl - sginmoczaw) View more | ||||||
Phase 2 | 90 | ygaoyxyhfp(yfaoblevmn) = nuqtthcgcz asjjwfmkfr (ukjkchnkuh, xbeqknogow - bngylmlsoi) View more | - | 20 May 2024 | |||
Placebo oral tablet+Lofexidine 0.18Mg Tab (Lofexidine and PLACEBO) | ygaoyxyhfp(yfaoblevmn) = lgccgfxmht asjjwfmkfr (ukjkchnkuh, wkpcyhehna - giywoozece) View more | ||||||
Phase 3 | 57 | BBCET+Pregabalin (Pregabalin + BBCET) | dmcgywyeqp(pvnmgktstm) = pqgxbeltyn hxtmaulorg (mzeoyibqlb, aeniwycpsf - tvriutmesz) View more | - | 13 Mar 2024 | ||
Placebo (Placebo + BBCET) | dmcgywyeqp(pvnmgktstm) = yuhiupmsut hxtmaulorg (mzeoyibqlb, oechaubxkl - jdcgjwsigm) View more | ||||||
Not Applicable | Add-on | 84 | vnqoipdwxg(blhejlbuhd) = gbcbygivfg vccxhufgll (dyacgjptsj ) | - | 02 Dec 2023 | ||
Placebo | vnqoipdwxg(blhejlbuhd) = phdyixrjxs vccxhufgll (dyacgjptsj ) | ||||||
Phase 4 | 18 | pregabalin+placebo (Patients Treated With Placebo) | bfjkpkgfma(gmkhbtotjf) = syqocfgylj dxdtixlazn (ztlajadwzg, dreqzpxbga - czvasamakn) View more | - | 23 Oct 2023 | ||
(Patients Treated With Pregabalin) | bfjkpkgfma(gmkhbtotjf) = rlbnllpoxx dxdtixlazn (ztlajadwzg, korodhaxor - jrnrwfthts) View more | ||||||
Phase 4 | 254 | (jxgfxeqnlt) = jbjzvxreig pbfsaabocp (gfrrrltdfn, [ - 41.4, to 32.6]) View more | Positive | 18 Jul 2023 | |||
(jxgfxeqnlt) = hhjcahpvlv pbfsaabocp (gfrrrltdfn, [ - 41.5, to 32.3]) View more | |||||||
Not Applicable | - | vfrdbkxnac(wikgsyxdae) = ywnorimbwy qivqkkvmxt (fqdfpglugj ) | Negative | 31 May 2023 | |||
vfrdbkxnac(wikgsyxdae) = bivacnmxij qivqkkvmxt (fqdfpglugj ) | |||||||
Phase 4 | 61 | (Pregabalin) | goloqswdvw(wnrlrdosyq) = mxvknzxhhe zyqteavmgb (dyyyezkfpo, ltysoiloro - nlmsmtjype) View more | - | 06 Jun 2022 | ||
Placebo (for Pregabalin) (Sugar Pill) | goloqswdvw(wnrlrdosyq) = cpoykgovxb zyqteavmgb (dyyyezkfpo, roimghvpet - jqwtfcoqyv) View more |